SERA News & Events

Reports Q4 revenue $10K vs. $24K last year. In February 2025, Sera completed an underwritten public offering of common stock and pre-funded warrants extending cash runway through 2028. "2025 marked a pivotal year for Sera as we moved from clinical validation to commercial execution," said Zhenya Lindgardt, CEO. "The publication of the landmark PRIME Study delivered strong, peer-reviewed evidence that the PreTRM Test improves outcomes and reduces costs, creating a compelling value proposition for payers. During the year we expanded engagement across our target states, advanced active discussions with both commercial and Medicaid payers, and invested deliberately in leadership, access and infrastructure to support us as we scale. With a strengthened balance sheet, extending our runway through 2028, we enter 2026 focused on converting this foundation into broader adoption, payer coverage, and measurable impact for the families we serve."

Sera Prognostics announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs, PRIME, study were accepted for publication in a peer-reviewed journal. The PRIME study's abstract data was selected as a late-breaking abstract for podium presentation earlier this year at the Society for Maternal-Fetal Medicine's, SMFM, annual meeting. "We look forward to sharing PRIME manuscript data upon publication at upcoming medical meetings and through events with our research analysts," said Zhenya Lindgardt, President and CEO of Sera Prognostics.

Sera Prognostics announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.